(R)-tert-butyl 4-(1-phenylethyl)piperazine-1-carboxylate | 944256-02-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: (R)-tert-butyl 4-(1-phenylethyl)piperazine-1-carboxylate
• 英文别名: 4-(1-phenylethyl)piperazine carboxylic acid tert-butyl ester；tert-butyl 4-[(1R)-1-phenylethyl]piperazine-1-carboxylate
• CAS: 944256-02-4
• 化学式: C₁₇H₂₆N₂O₂
• 分子量: 290.406
• InChiKey: VHUZTMWZJJEDSH-CQSZACIVSA-N

物化性质

• 沸点：
  368.4±35.0 °C(Predicted)
• 密度：
  1.070±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  32.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (R)-tert-butyl 4-(1-phenylethyl)piperazine-1-carboxylate 在 四甲基乙二胺 、 仲丁基锂 作用下， 以 四氢呋喃 、 正己烷 、 乙腈 为溶剂， 反应 38.0h， 生成 3-oxo-1,1-diphenyltetrahydrooxazolo[ 3,4-a]pyrazine-7-carboxylic acid 9H-fluoren-9-ylmethyl ester
  参考文献：
  名称：

  Synthesis and Separation of the Enantiomers of the Neuropeptide S Receptor Antagonist (9R/S)-3-Oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic Acid 4-Fluoro-benzylamide (SHA 68)

  摘要：

  This study reports the synthesis, chromatographic separation, and pharmacological evaluation of the two enantiomers of the neuropeptide S receptor (NPSR) antagonist (9R/S)-3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68). The (9R)-3-oxo-1, 1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (compound 10) and (9S)-3-oxo-1,1-diphenyl-tetrahydro-oxazolo [3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (compound 10a) were synthesized and their purity assessed by chiral chromatography. The absolute configuration of the enantiomer 10 has been assigned from the crystal structure of the corresponding (S)-phenyl ethyl amine derivative 8. Calcium mobilization studies performed on cells expressing the recombinant NPSR demonstrated that compound 10 is the active enantiomer while the contribution of 10a to the NPSR antagonist properties of the racemic mixture is negligible.

  DOI：

  10.1021/jm200138r
• 作为产物：
  描述：

  3-oxo-4-(1-phenylethyl)piperazine-1-carboxylic acid tert-butyl ester 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 以84%的产率得到(R)-tert-butyl 4-(1-phenylethyl)piperazine-1-carboxylate
  参考文献：
  名称：

  Synthesis and Separation of the Enantiomers of the Neuropeptide S Receptor Antagonist (9R/S)-3-Oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic Acid 4-Fluoro-benzylamide (SHA 68)

  摘要：

  This study reports the synthesis, chromatographic separation, and pharmacological evaluation of the two enantiomers of the neuropeptide S receptor (NPSR) antagonist (9R/S)-3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68). The (9R)-3-oxo-1, 1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (compound 10) and (9S)-3-oxo-1,1-diphenyl-tetrahydro-oxazolo [3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (compound 10a) were synthesized and their purity assessed by chiral chromatography. The absolute configuration of the enantiomer 10 has been assigned from the crystal structure of the corresponding (S)-phenyl ethyl amine derivative 8. Calcium mobilization studies performed on cells expressing the recombinant NPSR demonstrated that compound 10 is the active enantiomer while the contribution of 10a to the NPSR antagonist properties of the racemic mixture is negligible.

  DOI：

  10.1021/jm200138r

文献信息

• Urotensin II receptor antagonists
  申请人：Kinney William A.

  公开号：US20080318973A1

  公开（公告）日：2008-12-25

  This invention is directed to a compound of Formula (I): and forms thereof, wherein A, B, E, G, X and L 2 are as defined herein and their use as urotensin II receptor antagonists.

  这项发明涉及到化合物的公式(I)及其形式，其中A、B、E、G、X和L2如本文所定义，并且它们作为尿苷II受体拮抗剂的用途。
• Synthesis of Enantiopure Piperazines via Asymmetric Lithiation–Trapping of <i>N</i>-Boc Piperazines: Unexpected Role of the Electrophile and Distal <i>N</i>-Substituent
  作者：James D. Firth、Peter O’Brien、Leigh Ferris

  DOI：10.1021/jacs.5b11288

  日期：2016.1.20

  for the synthesis of enantiopure α-substituted piperazines via direct functionalization of the intact piperazine ring is described. The approach utilizes the asymmetric lithiation-substitution of an α-methylbenzyl-functionalized N-Boc piperazine using s-BuLi/(-)-sparteine or (+)-sparteine surrogate and provides access to a range of piperazines (as single stereoisomers). Optimization of the new methodology

  描述了一种通过完整哌嗪环直接官能化合成对映体纯 α-取代哌嗪的新方法。该方法利用 s-BuLi/(-)-sparteine 或 (+)-sparteine 替代物对 α-甲基苄基官能化的 N-Boc 哌嗪进行不对称锂化取代，并提供对一系列哌嗪（作为单一立体异构体）的访问。新方法的优化需要详细的机械研究。令人惊讶的是，发现影响产率和对映选择性的主要罪魁祸首是亲电子试剂（添加到反应烧瓶中的最后一种试剂）和远端 N 取代基。机理研究包括使用原位红外光谱优化锂化时间，鉴定锂化哌嗪的环断裂（可以通过空间位阻 N-烷基最小化），并使用新型“二胺开关”策略提高某些亲电子试剂的对映选择性。该方法展示了 Indinavir 合成中间体的制备以及 2,5-反式和 2,6-反式哌嗪的立体选择性合成。
• UROTENSIN II RECEPTOR ANTAGONISTS
  申请人：Kinney William A.

  公开号：US20110269768A1

  公开（公告）日：2011-11-03

  This invention is directed to a compound of Formula (I): and forms thereof, wherein A, B, E, G, X and L 2 are as defined herein and their use as urotensin II receptor antagonists.

  本发明涉及式（I）的化合物及其形式，其中A、B、E、G、X和L2的定义如本文所述，并且它们作为尿钠II受体拮抗剂的用途。
• WO2007/81995
  申请人：——

  公开号：——

  公开（公告）日：——
• US7915260B2
  申请人：——

  公开号：US7915260B2

  公开（公告）日：2011-03-29